SUSTAINABILITY & IMPACT
Impacting Healthcare
Since inception, ARCHIMED’s vision has been guided by the belief that human, animal, and environmental health are deeply interconnected. Through this One Health lens, we support our investments to achieve sustainable health outcomes for all. Sustainable investments seek to contribute to at least one of ARCHIMED’s Five Health Objectives and measure their impact on healthcare through dedicated indicators.
Five Health Objectives
Better Efficacy: the capability of a product or treatment to consistently produce the intended health benefit or therapeutic effect.
Better Efficiency: the ability to manufacture a product or deliver a service at a faster speed and/or reduced cost, without compromising quality or desired outcomes.
Better Safety: the prevention of unintended harm during the provision of products or services, prioritizing human, animal, and/or environmental well-being.
Better Accessibility: the ease with which products and services are available and within the reach of all stakeholders in need.
Better Affordability: the extent to which a product or service is financially accessible to stakeholders in need, considering their ability to pay.
HEALTH IMPACT FOCUS OF OUR COMPANIES
“By providing breakthrough neuroscience solutions that advance patient access and deliver life-changing outcomes, we expand brain health treatment options and empower healthcare providers around the world to act with speed and boldness to meet the global urgency of patient care.”
Chris Landon,
Natus Neuro CEO
“We envision a healthier, more sustainable world where scientific innovation and ethical responsibility go hand in hand. We partner with our clients to advance transformative research, guided by a steadfast commitment to environmental care, social impact, and strong governance across every stage of development.”
Debra Dow,
Symbio COO
“We believe that biotechnology must serve a greater purpose: making life-saving treatments more accessible to all. Our vision is to be a leader, not only through our scientific innovation contributing to human health, but also through our sustainable business practices.”
Dr. Maria Wurm,
ExcellGene Deputy CEO & Head of New Markets
SEE OUR PUBLICATIONS
